| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/29/2014 | EP2688555A1 Solid ambroxol-containing preparation |
| 01/29/2014 | EP2688553A1 Pharmaceutical composition for use in nasal administration containing corticoid, and a quinolone or fusidic acid |
| 01/29/2014 | EP2688552A1 A pharmaceutical composition for treating a disease in the oral cavity comprising rebamipide |
| 01/29/2014 | EP2688481A1 Connective tissue monitoring, compositions for connective tissue treatment and methods for treating connective tissue |
| 01/29/2014 | EP2688427A1 Serum cholesterol lowering drink and an improved method for lowering cholesterol |
| 01/29/2014 | EP2688405A1 Compositions containing polymeric, ionic compounds comprising imidazolium groups |
| 01/29/2014 | EP2688403A1 Opioid receptor ligands and methods of using and making same |
| 01/29/2014 | EP2688402A1 Methods for treating or preventing urological inflammation |
| 01/29/2014 | EP2688399A1 Methods and compositions for the generation of peracetic acid on site at the point-of-use |
| 01/29/2014 | EP2516437B1 Disubstituted heteroaryl-fused pyridines |
| 01/29/2014 | EP2515647B1 Pheromone compositions and methods of use |
| 01/29/2014 | EP2493894B1 Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| 01/29/2014 | EP2435435B1 Pyrimidine inhibitors of kinase activity |
| 01/29/2014 | EP2419736B1 Methods of assessing activity of a polysaccharide composition |
| 01/29/2014 | EP2418202B1 (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors |
| 01/29/2014 | EP2410857B1 P2x3, receptor antagonists for treatment of pain |
| 01/29/2014 | EP2401269B1 Indole derivatives as crth2 receptor antagonists |
| 01/29/2014 | EP2394999B1 Aminopyrazine derivative and medicine |
| 01/29/2014 | EP2189448B1 Processes for the Separation of 3-Benzazepine Racemates |
| 01/29/2014 | EP2181709B1 Synergic combination of analgesic compounds |
| 01/29/2014 | EP2146961B1 N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
| 01/29/2014 | EP2089388B1 Process for the synthesis of moxifloxacin hydrochloride |
| 01/29/2014 | EP2078010B1 Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| 01/29/2014 | EP2072051B1 Combination of azelastine and mometasone |
| 01/29/2014 | EP2046289B1 Compositions and kits of phenylephrine |
| 01/29/2014 | EP2032129B1 Compositions of phenylephrine useful for treatment of respiratory illness |
| 01/29/2014 | EP1948158B1 Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor |
| 01/29/2014 | EP1790637B1 Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient |
| 01/29/2014 | EP1654002B2 Compositions for delivery of therapeutics into the eyes |
| 01/29/2014 | EP1615879B1 Process for the production of 9-cis retinoic acid |
| 01/29/2014 | EP1539122B1 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 01/29/2014 | CN203408269U Special composite residue purification particle for human body |
| 01/29/2014 | CN1914224B HCV NS-3 serine protease inhibitors |
| 01/29/2014 | CN1849306B Matrix metalloproteinase inhibitors |
| 01/29/2014 | CN103547583A Novel cephalosporin derivative and medical composition containing same |
| 01/29/2014 | CN103547580A Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| 01/29/2014 | CN103547579A Fused imidazole derivatives useful as ido inhibitors |
| 01/29/2014 | CN103547575A Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| 01/29/2014 | CN103547570A Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists |
| 01/29/2014 | CN103547566A Aminoindane compounds and use thereof in treating pain |
| 01/29/2014 | CN103547564A Auto-magnetic metal salen complex compound |
| 01/29/2014 | CN103547563A Biphenyl derivatives useful as glucagon receptor antagonists |
| 01/29/2014 | CN103547562A 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease |
| 01/29/2014 | CN103547315A 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma |
| 01/29/2014 | CN103547284A Immunity inducing agent |
| 01/29/2014 | CN103547281A Compositions and methods for the treatment and prevention of cardiac ischemic injury |
| 01/29/2014 | CN103547278A Immunity induction agent |
| 01/29/2014 | CN103547273A Pre-filled syringe filling syringe having resin barrel with aqueous solution containing hyaluronic acid or salt thereof |
| 01/29/2014 | CN103547272A Peptide-based in vivo siRNA delivery system |
| 01/29/2014 | CN103547271A Modulation of apolipoprotein CIII (APOCIII) expression |
| 01/29/2014 | CN103547269A 抗癌剂组合物 Anticancer composition |
| 01/29/2014 | CN103547268A Treatment of solid tumours |
| 01/29/2014 | CN103547267A Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| 01/29/2014 | CN103547266A Pharmaceutical compositions |
| 01/29/2014 | CN103547265A Rapidly dissolving oral tablet |
| 01/29/2014 | CN103547264A Use of sigma ligands in diabetes type-2 associated pain |
| 01/29/2014 | CN103547263A Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| 01/29/2014 | CN103547262A Novel uses of licochalcone A |
| 01/29/2014 | CN103547261A Methods for treating COPD |
| 01/29/2014 | CN103547260A Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a CNS disorder |
| 01/29/2014 | CN103547259A 控制释放药物剂型 Controlled release pharmaceutical dosage form |
| 01/29/2014 | CN103547256A Treatment of inflammatory and infectious skin disorders |
| 01/29/2014 | CN103547254A Wrinkle-improving composition containing placenta-derived component |
| 01/29/2014 | CN103547250A Novel use of flavone-based compound |
| 01/29/2014 | CN103547240A Systems and methods for balancing and maintaining the health of the human autonomic nervous system |
| 01/29/2014 | CN103547173A Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition |
| 01/29/2014 | CN103547164A Milk-added, low-calorie black tea beverage |
| 01/29/2014 | CN103547152A Inhibitors of bromodomains as modulators of gene expression |
| 01/29/2014 | CN103540655A Application of MK5 gene for screening anti-liver cancer drug |
| 01/29/2014 | CN103539863A Application of low-sulfated heteroglycan prepared from brown alga and rich in glucuronic acid in preparation of medicament and health-care products for treating Parkinson's disease |
| 01/29/2014 | CN103539801A Podophyllotoxin derivative as well as salt, preparation method and application thereof |
| 01/29/2014 | CN103539797A Novel compounds of reverse turn mimetics and the use thereof |
| 01/29/2014 | CN103539795A Apixaban polymorph and preparation method thereof |
| 01/29/2014 | CN103539793A Thiazole carboxamide compounds and application thereof |
| 01/29/2014 | CN103539791A Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| 01/29/2014 | CN103539787A Isoandrographolide photoaffinity labeling molecular probe, preparation method and pharmaceutical composition of molecular probe |
| 01/29/2014 | CN103539785A 大麻素受体调节剂 Cannabinoid receptor modulators |
| 01/29/2014 | CN103539784A Heterocyclic benzamide compounds, pharmaceutical compositions as well as application thereof |
| 01/29/2014 | CN103539783A I-type crystal of dimaleate of tyrosine kinase inhibitor and preparation method thereof |
| 01/29/2014 | CN103539780A Substituted pyrazolone compounds as well as use method and application of substituted pyrazolone compounds |
| 01/29/2014 | CN103539779A Hydroxyl substituted benzene sulfonate of dabigatran etexilate and preparation method and usage thereof |
| 01/29/2014 | CN103539777A PI3 kinase regulator as well as use method and application of PI3 kinase regulator |
| 01/29/2014 | CN103539769A Macrocyclic compounds useful as inhibitors of kinases and HSP90 |
| 01/29/2014 | CN103539764A 12-p-methyl benzene acyloxy-14-deoxidized andrographolide photoaffinity labeling molecular probe, and preparation method and pharmaceutical composition thereof |
| 01/29/2014 | CN103539760A Phenoxy phenylacetic acid endothelin antagonist, and preparation method and application thereof |
| 01/29/2014 | CN103539735A Crystalline forms of a prolyl hydroxylase inhibitor |
| 01/29/2014 | CN103539731A Pyridine-2-amide compound as well as preparation method, pharmaceutical composition and use thereof |
| 01/29/2014 | CN103539722A Aryl-substituted methyl-connected bis-indoleacetic acid derivative and preparation method and application thereof |
| 01/29/2014 | CN103539709A N-(-1-hydro-indenyl-1-yl)sulfonamide compound and its preparation method and use |
| 01/29/2014 | CN103539695A Novel diphenyl ether substituted histone deacetylase inhibitor |
| 01/29/2014 | CN103539659A 2,4-dibenzyloxybenzoic acid derivative and preparation method and application thereof |
| 01/29/2014 | CN103536935A Photosensitizer-modified core-shell structure magnetic nanocomposites and preparation method and application thereof |
| 01/29/2014 | CN103536933A New application of siRNA (small interfering ribonucleic acid) of neural differentiation related gene BRSK2 |
| 01/29/2014 | CN103536931A Water-soluble beta-cyclodextrin polymer supramolecular inclusion complex of azithromycin and preparation method thereof |
| 01/29/2014 | CN103536929A Preparation method of HPMC (Hydroxyl Propyl Methyl Cellulose) liquor |
| 01/29/2014 | CN103536927A Edaravone composition freeze-dried powder injection |
| 01/29/2014 | CN103536926A Preparation method of chitosan oligosaccharide nanoparticle |
| 01/29/2014 | CN103536925A Application of cardiac glycoside compound in treatment of non-small cell lung cancer |
| 01/29/2014 | CN103536923A Formulations for enhanced bioavailability of orally administered polar agents |
| 01/29/2014 | CN103536922A Application of acyl-coenzyme A: cholesterol acyltransferase-2 (ACAT2) inhibitor in liver cancer growth inhibition |